RAPT Therapeutics to Present at the Jefferies Virtual Global Healthcare Conference
May 26 2020 - 8:00AM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases, today announced that Brian Wong, M.D.,
Ph.D., President and CEO, will present a corporate update and
company overview at the Jefferies 2020 Healthcare Conference on
Tuesday, June 2nd at 9:30 a.m. Eastern Time.
A live webcast and audio archive of the presentation may be
accessed on the RAPT Therapeutics website
at https://investors.rapt.com/events-and-presentations. Please
connect to the website 10 minutes prior to the presentation to
ensure adequate time for any software downloads that may be
necessary to listen to the webcast.
About RAPT Therapeutics, Inc.RAPT
Therapeutics is a clinical stage immunology-based biopharmaceutical
company focused on discovering, developing and commercializing oral
small molecule therapies for patients with significant unmet needs
in oncology and inflammatory diseases. Utilizing its proprietary
discovery and development engine, the Company is developing highly
selective small molecules designed to modulate the critical immune
drivers underlying these diseases. RAPT has discovered and advanced
two unique drug candidates, FLX475 and RPT193, each targeting C-C
motif chemokine receptor 4 (CCR4), for the treatment of cancer and
inflammation, respectively. The Company is also pursuing a range of
targets, including hematopoietic progenitor kinase 1 (HPK1)
and general control nonderepressible 2 (GCN2)), that are in the
discovery stage of development.
Media Contact: Angela Bitting media@rapt.com (925) 202-6211
Investor Contact: Sylvia Wheeler swheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Sep 2023 to Sep 2024